Highlights of This Issue 3097

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3099 CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla
Patrick Hwu

CCR Translations

3102 Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo
See related article, p. 3140

3105 Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
Manmeet S. Ahluwalia and Jeremy N. Rich
See related article p. 3307

Molecular Pathways

3108 Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

Reviews

3113 Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121 Nanotechnology: Future of Oncotherapy
Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

CANCER THERAPY: CLINICAL

3131 Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
Muriel Hannon, Yves Bega, Grégoire Eh, Sophie Servais, Laurence Seidel, Carlos Gaur, Johan Maertens, Tessa Kerre, Coline Daume, Muriel de Bock, Marianne Fillet, Aurélie Or, Evelyne Willems, André Godhot, Stéphanie Humblet-Baron, and Frédéric Baron

3140 PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
See related commentary, p. 3102

3149 Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA⁺ Liver Metastases
Steven C. Katz, Rachel A. Burga, Elise McCormack, Li Juan Wang, Wesley Mooring, Gary R. Point, Pranay D. Khare, Mitchell Thorn, Qiangzhong Ma, Brian F. Stainken, Earle A. Amanah, Robin Davies, N. Joseph Espat, and Richard P. Junghans

3160 Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Laster, Jason Jiang, Coumaran Egile, and Farrukh T. Awan

3170 Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3178 Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Cia Franco, Yuko Nakazaki, David Nemers, Chandrakot P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, and Glenn Dranoff

PERSONALIZED MEDICINE AND IMAGING

3187 Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
3196 Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Vivore Streng, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meliin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, and Lin Wu

CANCER THERAPY: PRECLINICAL
3204 Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinhäuser, Federico Roncaroli, Rickmer Braren, and Natalia S. Pellegrata

3216 Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

3230 HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Robbie Carson, Basak Celutki, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Pree-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, and Sandra Van Schaeybroeck

3241 Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma

3252 An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Jyoti Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakana, Josh Tanguay, Susan Spencer, Seerdevi Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haverty, Paul Polakis, and Ron Firestein

3263 Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate
Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mori, Charlotte M. Huijts, Horne Wildes, Santosh Bharti, Zhe Zhang, Cesar A. Santa-Maria, Hualing Tsai, Chi V. Dang, Vered Starems, Zaver M. Bhujwalla, and Saraswati Sukumar

3274 The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment

3286 XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A

3298 A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Helga Raab, Robert Sotiano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John Flygare, and Andrew G. Polson

BIOLOGY OF HUMAN TUMORS
3307 Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, Marianne Labussiere, Karima Mokhtari, Pietro Zoppoli, Yannick Marie, Aurelie Bruno, Blandine Boisselier, Marine Giry, Julien Savatovsky, Mehdi Touat, Hayat Belaid, Aurelie Kamoun, Ahmed Idbaih, Carolina Houillier, Feng R. Luo, Jean-Charles Soria, Josep Tabernero, Marica Eoli, Rosina Paterra, Stephen Yip, Kevin Petrecca, Jennifer A. Chan, Gaetano Finocchiaro, Anna Lasorella, Marc Sanson, and Antonio Iavarone
See related commentary, p. 3105

3318 Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting
Hongda Chen, Manuela Zucknick, Simone Werner, Phillip Knebel, and Hermann Brenner
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

Genetic Modulation of Neurocognitive Function in Glioma Patients
Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire

About the Cover
The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.